Esperion Therapeutics (ESPR) Other Non-Current Assets (2019 - 2022)

Esperion Therapeutics has reported Other Non-Current Assets for 4 years, with the latest figure at $50.0 million in Q3 2022.

• For the quarter ending Q3 2022, Other Non-Current Assets changed 0.0% year-over-year to $50.0 million; the trailing twelve-month figure through Sep 2022 stood at $50.0 million (changed 0.0% YoY), and the FY2021 full-year result was $50.0 million, changed N/A from the prior year.
• Other Non-Current Assets for Q3 2022 stood at $50.0 million, roughly flat from $50.0 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $50.0 million in Q3 2021, with the low at $928000.0 in Q2 2019.
• Historically, Other Non-Current Assets has averaged $23.3 million across 4 years, with a median of $1.3 million in 2020.
• The largest YoY upside for Other Non-Current Assets was 39.44% in 2020 against a maximum downside of 22.21% in 2020.
• Esperion Therapeutics' Other Non-Current Assets stood at $928000.0 in 2019, then jumped by 39.44% to $1.3 million in 2020, then soared by 3763.99% to $50.0 million in 2021, then changed by 0.0% to $50.0 million in 2022.
• The last three Other Non-Current Assets figures came in at $50.0 million (Q3 2022), $50.0 million (Q2 2022), and $50.0 million (Q1 2022), per Business Quant data.